CXCR2 and prostate carcinoma: Within tumors, CXCR2 ligands are capable of inducing EMT, a phenomenon that has been demonstrated in vitro with breast cancer cells (CXCL8/IL-8) [85], colon cancer cells (CXCL5) [86], hepatocellular carcinoma cells (CXCL5) [87], ovarian cancer cells (CXCL8/IL-8) [88], pancreatic cancer cells (CXCL5) [89], and prostate cancer cells (CXCL1) [90].